MXCT - MaxCyte announces departure of founder and CEO Doug Doerfler
2023-12-11 16:43:31 ET
More on MaxCyte
- MaxCyte May Benefit From Potential Gene Therapy Approval
- MaxCyte, Inc. (MXCT) Q3 2023 Earnings Call Transcript
- Gene editing stocks mixed despite world’s first CRISPR drug approval
- Biggest stock movers today: BlackBerry, Clorox, Rivian Automotive and more
- Seeking Alpha’s Quant Rating on MaxCyte
For further details see:
MaxCyte announces departure of founder and CEO Doug Doerfler